Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Blood (2019) 134 (Supplement_1): 3010.

https://doi.org/10.1182/blood-2019-129902

Published: 2019

Journal Articles

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?

Daniela De Benedittis, MD, Luana Fianchi, MD, Pasquale Niscola, MD PhD, Annalina Piccioni, MD, Ambra Di Veroli, MD, Alessia Campagna, MD, Stefano Mancini, MD, Nicoletta Villivà, Sara Mohamed, MD, Ida Carmosino, Marianna Criscuolo, Susanna Fenu, Maria Antonietta Aloe Spiriti, MD, Francesco Buccisano, MD, Massimo Breccia, MD, Marco Mancini, Roberto Latagliata

Blood (2018) 132 (Supplement 1): 5516.

https://doi.org/10.1182/blood-2018-99-117069

Published: 2018

Journal Articles

Response to Erythropoietin in Different Karyotipic Subsets of Myelodysplastic Syndromes (MDS) and MDS with Sideroblasts: Multicentric Real-Life Experience from the Grom-L Cooperative Group

Blood (2017) 130 (Supplement 1): 4262.

https://doi.org/10.1182/blood.V130.Suppl_1.4262.4262

Published: 2017

Journal Articles

Is Deferasirox Safe and Effective in Very Elderly Patients (> 75 Years) with Myelodysplastic Syndromes and Transfusional Iron Overload?

Roberto Latagliata, Pasquale Niscola, MD, Antonio Volpe, MD, Claudia Baratè, MD PhD, Alessia Campagna, MD, Antonella Poloni, PhD MD, Chiara Sarlo, MD, Laura Faglioni, MD, Daniela De Benedictis, MD, Ida Carmosino, Susanna Fenu, Maria Antonietta Aloe Spiriti, MD, Sara Galimberti, PhD MD, Massimo Breccia, MD PhD, Robin Foà, MD, Carlo Finelli, MD

Blood (2017) 130 (Supplement 1): 4263.

https://doi.org/10.1182/blood.V130.Suppl_1.4263.4263

Published: 2017

Journal Articles

Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment

Roberto Latagliata, MD, Pasquale Niscola, MD, Maria Antonietta Aloe Spiriti, MD, Ida Carmosino, Laura Cesini, MD, Chiara Sarlo, MD, Annalina Piccioni, MD, Alessia Campagna, MD, Maria Lucia De Luca, Federico Vozella, Melissa Campanelli, MD, Marco Mancini, MD, Massimo Breccia, MD, Giuseppe Avvisati, MD, Agostino Tafuri, MD, Paolo de Fabritiis, MD, Giuliana Alimena, MD, Corrado Girmenia, MD

Blood (2016) 128 (22): 5544.

https://doi.org/10.1182/blood.V128.22.5544.5544

Published: 2016

Journal Articles

Cost Description on a Cohort of 659 Patients with Adult MDS Included into the Italian Lazio Region Registry (the GROM-L)

Carlo Lazzaro, Dr., Maria Antonietta Aloe-Spiriti, MD, Maria Teresa Voso, MD, Roberto Latagliata, MD, Francesco Buccisano, MD, Susanna Fenu, MD, Luca Maurillo, MD, Roberto Ricci, Dr., Luana Fianchi, Gina Zini, MD Prof.

Blood (2015) 126 (23): 5237.

https://doi.org/10.1182/blood.V126.23.5237.5237

Published: 2015

Journal Articles

Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile

Massimo Breccia, Maria Teresa Voso, M.D., Luca Maurillo, MD, Pasquale Niscola, Luana Fianchi, MD, Maria Antonietta Aloe Spiriti, Francesco Buccisano, Sabrina Pelliccia, Susanna Fenu, Andrea Tendas, Roberto Latagliata, MD, Giuliana Alimena

Blood (2013) 122 (21): 5229.

https://doi.org/10.1182/blood.V122.21.5229.5229

Published: 2013

Journal Articles

Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials

Massimo Breccia, Maria Teresa Voso, M.D., Luca Maurillo, MD, Pasquale Niscola, Francesco Autore, MD, Maria Antonietta Aloe Spiriti, Francesco Buccisano, MD, Caterina Tatarelli, Andrea Tendas, Susanna Fenu, Roberto Latagliata, MD, Giuliana Alimena

Blood (2013) 122 (21): 5203.

https://doi.org/10.1182/blood.V122.21.5203.5203

Published: 2013

Journal Articles

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Carlo Finelli, M.D., Cristina Clissa, M.D., Maria Teresa Voso, Maria Antonietta Aloe Spiriti, Massimo Breccia, Gianluca Gaidano, MD, PhD, Monica Crugnola, M.D., Maria Benedetta Giannini, M.D., Costanza Bosi, MD, Virginia Naso, MD, Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Giovanni Martinelli, Lucio Cocco, MD, Michele Baccarani, MD

Blood (2012) 120 (21): 4951.

https://doi.org/10.1182/blood.V120.21.4951.4951

Published: 2012

Journal Articles

Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience

Blood (2012) 120 (21): 4958.

https://doi.org/10.1182/blood.V120.21.4958.4958

Published: 2012

Journal Articles

Distinct Phenotypic and Functional Immunological Alterations Characterize the Peripheral Blood Compartment of Patients with Diffuse Large B Cell Lymphoma (DLBCL).

M. Christina Cox, MD, Raffaella La Scaleia, Sabrina Pelliccia, Arianna Di Napoli, Eleonora Alma, Simone Battella, Virginia Naso, Alessandra Porzia, Luigi Ruco, Maria Antonietta Aloe Spiriti, Vincenzo Ambrogi, Fabrizio Mainiero, Sergio Amadori, Bruno Monarca, Angela Santoni, Gabriella Palmieri

Blood (2012) 120 (21): 2653.

https://doi.org/10.1182/blood.V120.21.2653.2653

Published: 2012

Journal Articles

Diffuse-Large-B-Cell Lymphoma Patients with Secretory IgM Monoclonal Component Are A Very Poor Prognostic Subset.

M. Christina Cox, MD, Arianna Di Napoli, Stefania Scarpino, Elena Cavalieri, Virginia Naso, MD, Caterina Talerico, Gerardo Salerno, Caterina Tatarelli, Maria Antonietta Aloe Spiriti, Bruno Monarca, Sergio Amadori, Luigi Ruco

Blood (2012) 120 (21): 2659.

https://doi.org/10.1182/blood.V120.21.2659.2659

Published: 2012

Journal Articles

Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q)

Esther Natalie Oliva, MD, Francesco Nobile, MD, Francesca Ronco, MD, Caterina Alati, MD, Fortunato Morabito, MD, Antonella Poloni, MD, Agostino Cortelezzi, MD, Maria Antonietta Aloe Spiriti, MD, Alessandra Ricco, Antonio Volpe, MD, Enrico Balleari, MD, Grazia Sanpaolo, MD, Massimo Breccia, MD, Cristina Clissa, Giuliana Alimena, MD, Roberto Latagliata, MD

Blood (2010) 116 (21): 2927.

https://doi.org/10.1182/blood.V116.21.2927.2927

Published: 2010

Journal Articles

Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.

Esther Natalie Oliva, MD, Roberto Latagliata, MD, Fortunato Morabito, MD, Antonella Poloni, MD, Riccardo Ghio, MD, Agostino Cortelezzi, MD, Carlo Finelli, MD, Claudia Baratè, MD, Francesca Ronco, MD, Maria Antonietta Aloe Spiriti, MD, Alessandra Ricco, MD, Massimo Breccia, MD, Caterina Alati, MD, Giulia Praticò, MD, Francesco Nobile, MD

Blood (2009) 114 (22): 2763.

https://doi.org/10.1182/blood.V114.22.2763.2763

Published: 2009

Journal Articles

Quality of Life in Myelodysplastic Syndromes and Physicians' Perception.

Esther Natalie Oliva, MD, Valeria Santini, MD, Poloni Antonella, MD, Vincenzo Liso, MD, Daniela Cilloni, MD, Adelmo Terenzi, MD, Patrizia Guglielmo, MD, Riccardo Ghio, MD, Agostino Cortelezzi, MD, Giampietro Semenzato, MD, Cristina Clissa, MD, Flavia Salvi, MD, Oreste Villani, MD, Maria Antonietta Aloe Spiriti, MD

Blood (2009) 114 (22): 3822.

https://doi.org/10.1182/blood.V114.22.3822.3822

Published: 2009

Journal Articles

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Blood (2008) 112 (11): 2680.

https://doi.org/10.1182/blood.V112.11.2680.2680

Published: 2008

Journal Articles

Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome

Esther Natali e Oliva, MD, Cristina Clissa, MD, Valeria Santini, Antonella Poloni, MD, Vincenzo Liso, MD, Daniela Cilloni, MD, PhD, Adelmo Terenzi, MD, Stefana Impera, MD, Alessandro Levis, MD, Agostino Cortelezzi, MD, Riccardo Ghio, MD, Giampietro Semenzato, MD, Oreste Villani, MD, Maria Antonietta Aloe Spiriti, MD

Blood (2008) 112 (11): 2363.

https://doi.org/10.1182/blood.V112.11.2363.2363

Published: 2008

Journal Articles

Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem

Roberto Latagliata, Maria Concetta Petti, Susanna Fenu, Marco Mancini, Maria Antonietta Aloe Spiriti, Massimo Breccia, Gregorio A. Brunetti, Giuseppe Avvisati, Francesco Lo Coco, Franco Mandelli

Blood (2002) 99 (3): 822–824.

https://doi.org/10.1182/blood.V99.3.822

Published: 2002

NARROW

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?

Response to Erythropoietin in Different Karyotipic Subsets of Myelodysplastic Syndromes (MDS) and MDS with Sideroblasts: Multicentric Real-Life Experience from the Grom-L Cooperative Group

Is Deferasirox Safe and Effective in Very Elderly Patients (> 75 Years) with Myelodysplastic Syndromes and Transfusional Iron Overload?

Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment

Cost Description on a Cohort of 659 Patients with Adult MDS Included into the Italian Lazio Region Registry (the GROM-L)

Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile

Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience

Distinct Phenotypic and Functional Immunological Alterations Characterize the Peripheral Blood Compartment of Patients with Diffuse Large B Cell Lymphoma (DLBCL).

Diffuse-Large-B-Cell Lymphoma Patients with Secretory IgM Monoclonal Component Are A Very Poor Prognostic Subset.

Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q)

Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.

Quality of Life in Myelodysplastic Syndromes and Physicians' Perception.

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome

Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only